Open access

398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy
Steven O’Day, Anthony El khoueiry, Chethan Ramamurthy, Andrea Bullock, Irina Shapiro, Serina, Haiyong Han, Lernik Ohanjanian Namagerdi, Remigiusz Kaleta, Anna Wijatyk, Olivia Wijatyk, Waldo Ortuzar, Marek Ancukiewicz, Jennifer Buell, Dhan Chand, Michael Gordon

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A242; DOI: 10.1136/jitc-2020-SITC2020.0398
400 CoupledCARTM technology for treating thyroid cancer
Xingchen Liu, Keshu Zhou, Yong Huang, Chengfei Pu, Zhiyuan Cao, Ruihong Zhu, Haiyang Tang, Zhipeng Huang, Hang Yang, Xi Huang, Yongping Song, Renbin Liu, Zhao Wu, Lei Xiao, Lei Xiao

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A243-A244; DOI: 10.1136/jitc-2020-SITC2020.0400
404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)
Keun-Wook Lee, Hyun Chung, Won Seog Kim, Laura Chow, Nehal Lakhani, Wells Messersmith, Yung-Jue Bang, Patricia LoRusso, Philip Fanning, Pierre Squifflet, Feng Jin, Alison Forgie, Hong Wan, Jaume Pons, Sophia Randolph, Justin Gainor

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A245-A246; DOI: 10.1136/jitc-2020-SITC2020.0404
403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors
Timothy Price, Sant Chawla, Gerald Falchook, Hans Prenen, Iwona Lugowska, Vivek Subbiah, Jose Monzon, Yuichi Ozawa, Tobias Arkenau, Caio Rocha Lima, Yasutoshi Kuboki, Tomohiro Nishina, Mun Hui, Erik Rasmussen, Hansen Wong, Saltanat Najmi, Nooshin Sadraei

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A245; DOI: 10.1136/jitc-2020-SITC2020.0403
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)
Rachel Sanborn, Ralph Hauke, Nashat Gabrail, Mark O’Hara, Nina Bhardwaj, Rodolfo Bordoni, Michael Gordon, Danny Khalil, Maen Abdelrahim, Thomas Marron, Thomas Hawthorne, Lawrence Thomas, Tracey Rawls, Mark Rogalski, Diego Alvarado, Laura Vitale, Tibor Keler, Michael Yellin

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A246; DOI: 10.1136/jitc-2020-SITC2020.0405
406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies
Michael Yellin, Tracey Rawls, Diane Young, Philip Golden, Laura Vitale, Li-Zhen He, Lawrence Thomas, Tibor Keler

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A247; DOI: 10.1136/jitc-2020-SITC2020.0406
409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)
John Stewart, John Strickler, Niharika Mettu, Shannon MacLaughlan, Donna Niedzwiecki, Edward Levine, Daniel Blazer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A248-A249; DOI: 10.1136/jitc-2020-SITC2020.0409
408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors
Kevin Harrington, Eileen Parkes, Jared Weiss, Mathew Ingham, Andrés Cervantes, Emiliano Calvo, Matthew Riese, Ute Klinkhardt, Patricia Sikken, Michael Schmohl, Elena Garralda

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A248; DOI: 10.1136/jitc-2020-SITC2020.0408
410 Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers
Colette Shen, Jessica Frakes, Jiaxin Niu, Jared Weiss, Jimmy Caudell, Katherine Jameson, Patricia Said, Tanguy Seiwert

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A249; DOI: 10.1136/jitc-2020-SITC2020.0410
411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients
Anthony El-Khoueiry, Jacob Thomas, Anthony Olszanski, Nilofer Azad, Lewis Bender, Ian Walters, Giles Whalen, Diana Hanna, Matthew Ingham, Lilian Siu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A250; DOI: 10.1136/jitc-2020-SITC2020.0411

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages